DURECT Announces Intent to Submit NDA for POSIDUR™ for Post-Operative Analgesia
12:14 EDT 6 Aug 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
CUPERTINO, Calif., Aug. 6, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed its pre-NDA communications with the United States Food and Drug Administration (FDA) regarding POSIDUR™ (SABER®-Bupivac...
Other Sources for this Article
More From BioPortfolio on "DURECT Announces Intent to Submit NDA for POSIDUR™ for Post-Operative Analgesia"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
